These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds. Hongthong K; Ratanaphan A Curr Cancer Drug Targets; 2016; 16(7):606-17. PubMed ID: 26845433 [TBL] [Abstract][Full Text] [Related]
7. A novel ruthenium(ii) gallic acid complex disrupts the actin cytoskeleton and inhibits migration, invasion and adhesion of triple negative breast tumor cells. Graminha AE; Honorato J; Correa RS; Cominetti MR; Menezes ACS; Batista AA Dalton Trans; 2021 Jan; 50(1):323-335. PubMed ID: 33305766 [TBL] [Abstract][Full Text] [Related]
8. Intracellular Localization Studies of the Luminescent Analogue of an Anticancer Ruthenium Iminophosphorane with High Efficacy in a Triple-Negative Breast Cancer Mouse Model. Miachin K; Del Solar V; El Khoury E; Nayeem N; Khrystenko A; Appelt P; Neary MC; Buccella D; Contel M Inorg Chem; 2021 Dec; 60(24):19152-19164. PubMed ID: 34846878 [TBL] [Abstract][Full Text] [Related]
9. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells. Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527 [TBL] [Abstract][Full Text] [Related]
10. The anti-cancer effect of series of strained photoactivatable Ru(II) polypyridyl complexes on non-small-cell lung cancer and triple negative breast cancer cells. Fayad C; Audi H; Khnayzer RS; Daher CF J Biol Inorg Chem; 2021 Feb; 26(1):43-55. PubMed ID: 33221954 [TBL] [Abstract][Full Text] [Related]
11. E3 ubiquitin ligase CHIP attenuates cellular proliferation and invasion abilities in triple-negative breast cancer cells. Xu J; Wang H; Li W; Liu K; Zhang T; He Z; Guo F Clin Exp Med; 2020 Feb; 20(1):109-119. PubMed ID: 31845129 [TBL] [Abstract][Full Text] [Related]
12. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells. Varghese E; Samuel SM; Varghese S; Cheema S; Mamtani R; Büsselberg D Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30563138 [TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells. Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246 [TBL] [Abstract][Full Text] [Related]
15. Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways. Bai X; Ali A; Lv Z; Wang N; Zhao X; Hao H; Zhang Y; Rahman FU Eur J Med Chem; 2021 Nov; 224():113689. PubMed ID: 34293698 [TBL] [Abstract][Full Text] [Related]
16. Ru(II)-Naphthoquinone complexes with high selectivity for triple-negative breast cancer. Oliveira KM; Peterson EJ; Carroccia MC; Cominetti MR; Deflon VM; Farrell NP; Batista AA; Correa RS Dalton Trans; 2020 Nov; 49(45):16193-16203. PubMed ID: 32329497 [TBL] [Abstract][Full Text] [Related]
17. Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, and Angiogenesis Inhibition in Triple-Negative Breast Cancer Cells. Ahmed SA; Mendonca P; Messeha SS; Soliman KFA Molecules; 2023 Sep; 28(18):. PubMed ID: 37764312 [TBL] [Abstract][Full Text] [Related]
18. Rationally Designed Ruthenium Complexes for Breast Cancer Therapy. Golbaghi G; Castonguay A Molecules; 2020 Jan; 25(2):. PubMed ID: 31936496 [TBL] [Abstract][Full Text] [Related]
19. miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells. Crippa E; Folini M; Pennati M; Zaffaroni N; Pierotti MA; Gariboldi M Oncotarget; 2016 Apr; 7(14):18594-604. PubMed ID: 26919240 [TBL] [Abstract][Full Text] [Related]
20. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs. Atipairin A; Canyuk B; Ratanaphan A Breast Cancer Res Treat; 2011 Feb; 126(1):203-9. PubMed ID: 20878461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]